| Drug General Information |
| Drug ID |
D0CY1B
|
| Former ID |
DCL000010
|
| Drug Name |
CYC116
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Company |
Cyclacel Limited
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H20N6OS
|
| Canonical SMILES |
CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4
|
| InChI |
1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
|
| InChIKey |
GPSZYOIFQZPWEJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
11618518, 16832086, 24424536, 43014321, 46393965, 50521546, 99436925, 103652037, 103904403, 104120139, 114518369, 124757050, 125163854, 125329932, 125650062, 131480715, 134339467, 135685404, 135685405, 135685424, 136367344, 136367981, 136920315, 137276048, 141791974, 144115863, 152037316, 152258254, 152344039, 160647090, 162011811, 162037480, 162202552, 164194001, 170481285, 174561022, 180190851, 185965274, 188899569, 223653845, 223705256, 223964817, 228221334, 246870915, 249814521, 251963051, 252215210, 252451655, 252543304
|
| Target and Pathway |
| Target(s) |
Aurora kinase B |
Target Info |
Inhibitor |
[2]
|
|---|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[2]
|
| Aurora kinase A |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04114:Oocyte meiosis
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Aurora B signaling
|
|
Signaling by Aurora kinases
|
|
Aurora C signaling
|
|
FOXM1 transcription factor network
|
|
Aurora A signalinghif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkaurora_b_pathway:Aurora B signaling
|
|
Integrin-linked kinase signaling
|
|
PLK1 signaling events
|
|
Aurora A signaling
|
|
Reactome
|
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Separation of Sister Chromatids
|
|
Resolution of Sister Chromatid Cohesion
|
|
RHO GTPases Activate Formins
|
|
Mitotic PrometaphaseR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
WikiPathways
|
Mitotic Metaphase and Anaphase
|
|
Mitotic Prometaphase
|
|
Regulation of Microtubule Cytoskeleton
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
APC/C-mediated degradation of cell cycle proteinsWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP437:EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Gastric Cancer Network 1
|
|
Integrated Breast Cancer Pathway
|
|
APC/C-mediated degradation of cell cycle proteins
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00560716) A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Cyclacel. |
|---|
